Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.

Abstract

There is an evidence to suggest that cdc25B phosphatase is an oncogenic. We hypothesized that cdc25B gene may be expressed in tumors of patients with non-small cell lung cancer (NSCLC) and affect their clinical outcome. Expression of cdc25B messenger RNA was evaluated by reverse transcription polymerase chain reaction in 55 non-small cell lung carcinomas and adjacent histological normal lung samples using LightCycler. The data was analyzed in reference to clinicopathological data and survival data. There was no difference of cdc25B expression level between the NSCLC tissue and normal lung tissue. There was no relationship between cdc25B gene expression and age, gender, N or T-status and clinical stage. However, the NSCLC patients with high cdc25B expression had significantly poor survival than the patients with low cdc25B expression (P=0.0173). Thus we suggest that cdc25B may predict poor survival.

• Authors: H Sasaki, H Yukiue, Y Kobayashi, M Tanahashi, S Moriyama, Y Nakashima, I Fukai, M Kiriyama, Y Yamakawa, Y Fujii
• Journal: Cancer letters (Cancer Lett) Vol. 173 Issue 2 Pg. 187-92 (Nov 28 2001) ISSN: 0304-3835 [Print] Ireland
• PMID: 11597794 (Publication Type: Journal Article)

Chemical References

• Cell Cycle Proteins
• CDC25B protein, human
• cdc25 Phosphatases

Topics

• Adenocarcinoma (diagnosis, metabolism, mortality)
• Age Factors
• Aged
• Aged, 80 and over
• Carcinoma, Non-Small-Cell Lung (diagnosis, metabolism, mortality)
• Carcinoma, Squamous Cell (diagnosis, metabolism, mortality)
• Cell Cycle Proteins (biosynthesis)
• Disease-Free Survival
• Female
• Humans
• Immunohistochemistry
• Lung (metabolism)
• Lung Neoplasms (diagnosis, metabolism, mortality)
• Lymphatic Metastasis
• Male
• Middle Aged
• Phosphorylation
• Prognosis
• Reverse Transcriptase Polymerase Chain Reaction
• Sex Factors
• Time Factors
• Treatment Outcome
• cdc25 Phosphatases (biosynthesis)